Obesity dipped in U.S. adults last year for first time in a decade
Category: News & Politics
Via: perrie-halpern • one month ago • 15 commentsBy: Denise Chow and Akshay Syal, M.D.
S E E D E D C O N T E N T
The Summary
- Obesity dipped slightly in U.S. adults last year for the first time in more than a decade, a study found.
- The researchers suggested that might be due, in part, to the rise of weight loss drugs like Ozempic.
- However, other medications or factors — such as the effects of the Covid pandemic — could also have played a role.
Obesity dipped slightly in U.S. adults last year, research found — the first time in more than a decade that the country has seen a downward trend. That might be due, in part, to the recent rise of blockbuster weightloss drugs like Ozempic, according to the study authors.
The findings, published Friday in the journal JAMA Health Forum, showed the most significant decrease in the South, particularly among women and adults ages 66 to 75.
The study looked at bodymass index measurements of more than 16.7 million adults across different geographic regions, age groups, sexes, races and ethnicities from 2013 through 2023. BMI measurements, which are a standard but limited way to estimate obesity as a ratio of weight to height, were gathered from electronic health records.
The researchers found that the prevalence of adult obesity in the U.S. decreased from 46% in 2022 to 45.6% in 2023. (Those are slightly higher shares than the estimate from the Centers for Disease Control and Prevention, which says around 40% of U.S. adults had obesity from 2021 to 2023.)
The results were not uniform across demographics and geographic regions, said Benjamin Rader, a computational epidemiologist at Boston Children's Hospital and an author of the study.
"In the U.S overall, obesity was on the decline, led by the South, but in some regions that wasn't the case," he said. "We also saw large drops among Black Americans, but we saw increases in obesity among Asian Americans."
Rader said the decline in the South is notable because that region also had the highest observed per-capita uptake of weight loss drugs, based on the researchers' analysis of insurance claims. But he acknowledged that any possible connection there needs further investigation.
The study authors also noted that the South experienced a disproportionately high number of Covid-19 deaths among people with obesity, which could have affected the overall data.
Dr. Michael Weintraub, an endocrinologist and clinical assistant professor at the New York University Grossman School of Medicine, said the results were in line with recent data from the CDC that showed a slight downtick in obesity prevalence among adults in the U.S. in the 2021-2023 period, as compared with the years from 2017 to 2020 (though severe obesity rose over that time).
"I find the data exciting, and with the prospect that we could be at the precipice of a shift in this obesity epidemic," said Weintraub, who was not involved in the new study. "But I hesitate to call this down-trending value in 2023 yet a trend."
Even if weight loss medications were a major factor in the decline in obesity, experts said more research is needed over longer periods of time to evaluate the new drugs' true impact.
"We know these medications are extremely effective, but we need a couple more years to see if this is truly a trend or if it's just a little blip and things will go back to where they were, or if it will get even worse," said Dr. Tannaz Moin, an endocrinologist and associate professor of medicine at the University of California, Los Angeles, who was not involved with the study.
Moin also pointed out that the new study only analyzed the dispensing of GLP-1 weight loss drugs — a category that includes Ozempic and Mounjaro. This type of medication is used to treat diabetes and obesity by helping to reduce a person's appetite and food intake. The drugs mimic a hormone that can make someone feel full.
But GLP-1 drugs are only a subset of prescriptions to treat obesity, Moin said, so a more comprehensive study of different medications could better capture any changes in trends. Weight loss drugs are also pricey, which may skew data on who is able to access the treatment.
Plus, the study's use of insurance claims data means people without coverage or who purchased weight loss drugs out of pocket were likely not captured in the results.
Moin said she was surprised by the drop in BMI observed in older people.
"That isn't the group that I would necessarily think to be the highest users of GLP-1 drugs because many would be in the Medicare age range," she said, adding that weight loss drugs can be difficult to obtain for those on Medicare. The Biden administration recently proposed a rule that would require Medicare and Medicaid to cover weight loss medications for people seeking obesity treatment.
Weintraub, meanwhile, cautioned that observed dips don't always indicate a long-term decline.
"We've been fooled by fluctuations in obesity prevalence in the past," he said. "We got excited about down-trending pediatric obesity rates in the early 2000s by the CDC, only for them to shoot up in the subsequent years."
Tags
Who is online
19 visitors
A win for big Pharma if true.
"We know these medications are extremely effective, but we need a couple more years to see if this is truly a trend or if it's just a little blip and things will go back to where they were, or if it will get even worse,"
I’ve heard that there is strong evidence that these drugs lose their efficacy after two years, and users balloon back up because the only thing that got them to lose weight was the lack of hunger caused by the drug. Once they’re hungry again they fall right back into the unhealthy lifestyle that they made no effort to correct. It’s actually a perfect scenario for Big Pharma. They get to reap temporary huge profits on massively overpriced drugs, and on the back end they receive the same unhealthy customers for their sick maintenance programs.
It's like the surgery people were having. Most of the people I know that had the surgery started gaining the weight back a couple of years after having it
sounds like a perfect perpetual motion machine for pharmaceutical companies. specialty prescription drugs advertised on television to be requested by name by consumers from their doctors. funny, it seems like all the illegal narcotics so popular 50 years ago have now been synthesized/modified for public consumption.
Obesity is an epidemic in America and is also the primary cause of our mental health crisis. To be mentally fit one must also be physically fit and spiritually fit. Our diets and sedentary lifestyles are the foundation of all our social and health problems in this country.
Avoid every aisle in the grocery store except the produce and meat counter. Carbs and sugars are the enemy. Get at least 30 minutes of exercise a day.
I wonder if there was a coinciding rise in the known side effects of using these weight loss drugs
Some of these were introduced first as type 2 diabetes treatments. There are some serious side effects from especially Ozempic. One sounds particularly nasty.
I remember, I even lost a good 20 lbs when I first started taking my type 2 meds. Insulin did not have that effect when eventually had to switch
Especially lowering your blood sugar, that can kill you.
yeah it can
I was losing weight before I was diagnosed with Type 2. Then the meds helped some but I got better with my diet and lost close to 30...but then....
Lol
by not having granulated sugar in my house for 15 years and controlling my carbs, I've shed 80 lbs ...
wow....But I love bread!
Due to inflation and the huge price increases in fuel costs, many people were unable to purchase as much food as in past years. You buy less food, you eat less, you lose weight. Simple.
What, obesity dipped!!! Did Trump get a haircut?
I'm fucked if I ever get seriously ill. I don't like pills or needles ...